Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06782282 · ClinicalTrials.gov registry record
A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older
A clinical trial of Community Acquired Pneumonia (CAP), sponsored by Pfizer.
- Active
- Registry status
- 22,234,435
- Enrollment target
- 1
- Study location
NCT06782282: Active study of Community Acquired Pneumonia (CAP), sponsored by Pfizer.
NCT06782282 is a study of Community Acquired Pneumonia (CAP) that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 22,234,435 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06782282, a study of Community Acquired Pneumonia (CAP), is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- 22,234,435 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn about how well the Prevnar 20 vaccine (PCV20) stops invasive pneumococcal disease (a group of severe infections caused by a bacteria called Streptococcus pneumoniae), pneumococcal pneumonia (a bacterial lung disease caused by the germ Streptococcus pneumoniae), all-cause pneumonia (pneumonia caused by any germ including bacteria, a virus, or a fungus), and lower respiratory tract infection (infection of the lower airways in the lung) in people 65 years and older. This study will use a database of people who have Medicare insurance with names and other identifying information removed. This study will include people who: * are 65 years and older, * live in one of the 50 United States or Washington DC, and * are enrolled in Medicare Fee-for-Service Parts A and B for at least 1 year. The study uses data that is already being collected and no treatment or vaccine will be given in the study. People that fit the description above will be followed in the Medicare database for about two years. Their information will be reviewed to see if they had vaccines for pneumonia or had certain health events, such as pneumonia or lower respiratory tract infection. The experiences of people that received Prevnar 20 will be compared to the experiences of people that did not receive the vaccine. This will help to show how well Prevnar 20 works at stopping invasive pneumococcal disease, pneumococcal pneumonia, all-cause pneumonia, and lower respiratory tract infection.
Primary Outcome
Presence of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes (1 inpatient or 1 outpatient in any diagnostic position) representing IPD
Conditions Studied
Study Locations (1)
New York
- Pfizer United States - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22,234,435 participants |
| Start Date | 2025-01-20 |
| Est. Completion | 2026-10-30 |
What the registry record for NCT06782282 still lists
NCT06782282 is an observational study that tracks outcomes without assigning an intervention. Its 22,234,435 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Community Acquired Pneumonia (CAP) appearing as the primary indexed condition, and to 0 interventions.
NCT06782282 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06782282 about?
NCT06782282 is a clinical study titled "A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older". The purpose of this study is to learn about how well the Prevnar 20 vaccine (PCV20) stops invasive pneumococcal disease (a group of severe infections caused by a bacteria called Streptococcus pneumoniae), pneumococcal pneumonia (a bacterial lung disease caused by the germ Streptococcus pneumoniae), ...
What is the current status of trial NCT06782282?
This trial is currently active not recruiting. The enrollment target is 22,234,435 participants. The study started on 2025-01-20. Estimated completion is 2026-10-30.
What conditions does trial NCT06782282 study?
This clinical trial studies the following conditions: Community Acquired Pneumonia (CAP).
Who is sponsoring clinical trial NCT06782282?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06782282 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Community Acquired Pneumonia (CAP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02485847 · 20,000,000 participants
IRIS Registry: Intelligent Research in Sight Registry
- NCT05678699 · 10,000,000 participants · NA
The Effects of Medicaid Policy Interventions on Racial Equity in Severe Maternal Morbidity
- NCT02693223 · 3,892,063 participants
Get With the Guidelines-Stroke Registry
- NCT06803498 · 3,000,000 participants
Delivery Room Intervention and Evaluation Network
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI